3D Organ Printing Market is Projected to Grow Billion Market Value till 2025 | Key Vendors - Organovo Holding, Luxexcel Group B.V, TeVido BioDevices, 3Dynamics Systems Ltd., Cyfuse Biomedical K.K

3D Organ Printing Market Report covers industry chain analysis, latest market trends & dynamics along with cost profit analysis of major key players which focuses on expansion rate, prices, competition, size, prices and value chain analysis of those leaders in the market. The 3D Organ Printing Market report covers the market landscape and its development prospects over the coming years.

Global 3D Organ Printing Market Synopsis:

The past four years, 3D Organ Printing market size to maintain the average annual growth rate from 2014 to 2019, Market analysts believe that in the next few years, 3D Organ Printing market size will be further expanded, we expect that by 2024, The market size of the 3D Organ Printing will reach at Higher rank.

Get Sample Study Papers of "Global 3D Organ Printing Market" @ https://www.businessindustryreports.com/sample-request/235106.

3D Organ Printing is a medical application of 3D printers. This procedure includes 3D printing of organ tissues and organs through layering of living cells. The procedure of 3D Organ Printing mainly involves of 3 stages, namely, pre- Organ Printing, Organ Printing, and post- Organ Printing. During the process of 3D Organ Printing, the cell function and viability of the output construct is preserved, which can be used for R&D in various medical areas. 3D Organ Printing is basically utilized for developing organ and tissue constructs, which can be used for R&D of drugs, scaffolds, and development of medical implants.

Expanding requirement for the medications and benefit of quick and cost-efficient production of bio-drugs using this technology are driving the segment further. The pharmaceutical industry is expected to raise multi-fold, thereby increasing the demand for medication pills.

The detailed segments and sub-segment of the 3D Organ Printing Market are given below:

1) Product Type Segmentation:

Magnetic Levitation
Inkjet-based
Laser-based
Others
2) Industry Segmentation:

The Kidney
The Liver
The Heart
The Cornea
Bones
3) Region Segmentation:

North America Country (United States, Canada)
South America
Asia Country (China, Japan, India, Korea)
Europe Country (Germany, UK, France, Italy)
Other Country (Middle East, Africa, GCC)
Top Leading player in Global 3D Organ Printing Market:

Organovo Holding, Luxexcel Group B.V, TeVido BioDevices, 3Dynamics Systems Ltd., Cyfuse Biomedical K.K., Aspect Biosystems Ltd., Stratasys Ltd., Voxeljet A.G., Bio3D Technologies Pte. Ltd., Materialise N.V., Envision TEC, Solidscape

Grab your discounted report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on "Global 3D Organ Printing Market Report 2020" @ https://www.businessindustryreports.com/check-discount/235106.

Latest Industry news:

Organovo (Dec. 16, 2019)

Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement

Organovo Holdings, Inc. and Tarveda Therapeutics, Inc. ("Tarveda"), a privately-held, clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced that they have entered into a definitive merger agreement under which Tarveda would merge with a wholly-owned subsidiary of Organovo in an all-stock transaction. Upon completion of the merger, the merged company would operate under the name Tarveda Therapeutics, Inc. and trade on the Nasdaq Stock Market LLC under the ticker symbol "TVDA."

Tarveda is primarily focused on the development of its pipeline of Pentarin miniature drug conjugates designed to selectively accumulate and retain anti-cancer payloads in solid tumor malignancies. Following the closing of the merger, Tarveda intends to continue to focus on advancing its two clinical stage oncology programs, PEN-866 and PEN-221, and on further development of novel conjugates from its proprietary miniature drug conjugate platform. At the closing of the merger, it is estimated that the combined company will have approximately $35 million of cash on hand that is expected to provide sufficient funding into the second half of 2021 to achieve key upcoming clinical data milestones on both clinical programs.

"After completing an extensive and thorough review of strategic alternatives, we are extremely pleased to announce this transaction with Tarveda, which we believe is in the best interest for our stockholders," said Taylor J. Crouch, President and Chief Executive Officer, Organovo. "Tarveda is advancing an innovative pipeline of clinical stage cancer therapies derived from the company's proprietary miniature drug conjugate platform. Tarveda is supported by a strong syndicate of investors including Novo A/S, Versant Ventures and ND Capital (NanoDimension) and a highly seasoned management team with prior public company experience."

"Our growing portfolio of miniature drug conjugates has the potential to represent much needed new treatment options for patients with solid tumor malignancies," said Drew Fromkin, President and Chief Executive Officer of Tarveda. "We are encouraged by the activity and tolerability demonstrated in Phase 1 human studies of our two clinical programs, PEN-866 and PEN-221. Our Pentarin miniature drug conjugates are designed to incorporate the best properties of small molecule drugs and antibody drug conjugates to form miniature drug conjugates that are effective at rapidly and deeply penetrating solid tumors while minimizing damage to healthy tissue. We are excited about this merger with Organovo and believe that this is the right point in Tarveda's trajectory to move forward as a publicly traded company given several upcoming clinical data milestones that we expect to be achieved in 2020 and 2021."

Tarveda expects the merger to provide the capital required to advance its two lead programs through the next set of clinical milestones and to generate novel conjugates from its Heat Shock Protein 90 (HSP90) binding miniature drug conjugate platform. PEN-866, the initial clinical program from Tarveda's HSP90 binding miniature drug conjugate platform, is designed to bind to the activated form of HSP90 in solid tumors to accumulate and retain its potent topoisomerase 1 inhibitor (SN-38) payload. PEN-866 is completing the Phase 1 dose escalation and safety portion of its "all comers" trial in various types of solid tumors and has shown to be well tolerated and demonstrated early clinical activity in heavily treated, advanced patients with a range of solid tumor malignancies. Beginning in early 2020, it is expected that PEN-866 will be evaluated in a Phase 2a study both as a single agent and as a combination therapy across a range of solid tumors that are sensitive to topoisomerase 1 inhibitors. PEN-221 is a miniature drug conjugate in clinical evaluation for the treatment of patients with solid tumors expressing somatostatin receptor 2 (SSTR2) on the cell surface and is linked to the potent tubulin inhibitor payload, DM1. In a Phase 1 study, PEN-221 was well tolerated and demonstrated early clinical activity. PEN-221 is currently being evaluated in a Phase 2a study for the treatment of patients with neuroendocrine tumors and small cell lung cancer.

Grab your report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on "Global 3D Organ Printing Market Report 2020" @ https://www.businessindustryreports.com/buy-now/235106/single.

Significant points in table of contents of Global 3D Organ Printing Market Report 2020:

1 3D Organ Printing Product Definition

2 Global 3D Organ Printing Market Manufacturer Share and Market Overview

3 Manufacturers 3D Organ Printing Business Introduction

4 Global 3D Organ Printing Market Segmentation (Region Level)

5 Global 3D Organ Printing Market Segmentation (Product Type Level)

6 Global 3D Organ Printing Market Segmentation (Industry Level)

7 Global 3D Organ Printing Market Segmentation (Channel Level)

8 3D Organ Printing Market Forecasts 2020-2024

9 3D Organ Printing Segmentation Product Type

10 3D Organ Printing Segmentation Industry

11 3D Organ Printing Cost of Production Analysis

12 Conclusions

About us:

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined - we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune - India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.